Institutional Investors Increased Biotech Stakes

Financial groups adjusted holdings in Sellas Life Sciences and ImmunityBio as the oncology sector sees growth.

Updated on Oct. 14, 2026 in Investing

Isometric editorial illustration of a glass medical vial on a clean industrial platform, symbolizing biotechnology investment. — Institutional investors increased stakes in Sellas Life Sciences and ImmunityBio, signaling confidence in the oncology pipeline's long-term commercial growth potential. AI Illustration. Upload story photo >

Live Poll

Is now a good time for you to increase investment in pharmaceutical stocks?

Institutional investors have increased their positions in Sellas Life Sciences and ImmunityBio, according to regulatory filings for the quarter ending September 30, 2026. This activity highlights market interest in the evolving oncology pipeline as major pharmaceutical companies pursue strategic acquisitions.

Why it matters

These investment shifts reflect broader efforts by major players like Johnson & Johnson to reach a $50 billion oncology sales goal by 2030. Such moves underscore the intense focus on developing new treatment pathways and expanding existing patient populations for cancer therapies.

Institutional holdings include Hennion & Walsh Asset Management's $3.67 million position in ImmunityBio and Everhart Financial Group's $2.96 million stake in Sellas Life Sciences. These positions align with significant year-to-date share price gains of 395% for ImmunityBio and 229% for Sellas.

The players

Johnson & Johnson

A global healthcare giant that develops pharmaceuticals and medical devices, currently prioritizing oncology for long-term revenue growth.

ImmunityBio

A clinical-stage immunotherapy company focusing on cancer treatments and managing product revenue from its bladder-cancer therapies.

Sellas Life Sciences

A biopharmaceutical company currently developing therapies for various cancer indications with upcoming clinical trial data releases.

The details

Investors adjusted equity positions following quarterly disclosure requirements, weighing clinical prospects against potential acquisition activity. Firms like Johnson & Johnson are leveraging internal cash reserves and strategic acquisitions, such as the $1 billion purchase of Firefly Bio, to secure future market share. This consolidation strategy aims to bolster oncology portfolios before upcoming regulatory milestones and data readouts for treatments like Anktiva and SLS009.

July 2026: Johnson & Johnson completed the acquisition of Firefly Bio.
September 30, 2026: The quarter closed for mandatory institutional ownership disclosures.
Q4 2026: Sellas Life Sciences expects Phase 2 results for SLS009.
January 6, 2027: The FDA is scheduled to decide on the expansion of Anktiva.
2030: Johnson & Johnson's target date for achieving $50 billion in oncology sales.

Money Landscape

This activity follows a pattern set by the SEC 13F filing requirements for institutional disclosure of large equity holdings. It highlights how investors track sector-specific growth trends, particularly in biotechnology where acquisition activity frequently precedes major portfolio shifts.

Investors should note that increased institutional interest in biotech firms often correlates with upcoming clinical trial results or regulatory decisions. Consult with a qualified financial professional to determine if exposure to volatile healthcare equities fits your personal risk tolerance and long-term goals.

The takeaway

The recent surge in institutional biotechnology holdings signals high market expectations for oncology innovation. Keep track of the FDA decision date for Anktiva on January 6, 2027, as it represents a key event for the sector that may influence future price volatility.